Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients
March 28, 2025
SAP-001 is Shanton’s lead investigational compound with First- and Best-in-Class potential in uncontrolled gout Shanton Pharma, a clinical-stage biotech company developing a novel treatment for